The 4 best GLP-1 telehealth programs of 2026
This category has never been more competitive, and that is very good news if you are the one buying. Four programs now compete on price, on speed, on formulary and on service — and the gap between the best of them and where this market was two years ago is enormous. Below, all four ranked on what can actually be verified: third-party ratings, live pricing and what happens when you ask for your money back.
Our score reflects price transparency, clinical access and shipping — not regulatory history, which is disclosed separately in each entry.
1. RemedyMeds
RemedyMeds is the most complete package on this page and the only one that includes your bloodwork. Labs through Quest, BioReference or LabCorp at no extra cost, clinician review inside 24 hours, free 48-hour cold-chain FedEx delivery and support seven days a week — that is a real service business, not a checkout page with a prescription attached. It is also the biggest: RemedyMeds acquired Thirty Madison (Keeps, Nurx, Cove) in an all-stock deal reported at over $500M in September 2025.
- Labs are included — the only program here where baseline bloodwork is part of the price rather than an errand you run yourself.
- Best switching experience in the category. RemedyMeds keeps you at your current dose from day one rather than restarting you at the bottom of the titration ladder, which is the single most annoying part of changing providers.
- Independently vetted twice over — Forbes Health scored the platform 4.3 out of 5, and it was accepted onto the Health-E Commerce FSA/HSA Store marketplace in October 2025, which involves third-party vendor review rather than a self-declared claim.
- A microdose tier at a lower price point for people who want to start gently, alongside standard semaglutide and tirzepatide.
- Worth knowing: the FDA sent RemedyMeds a warning letter on 9 September 2025 over its marketing language, its BBB file shows 455 complaints and an F grade, and the widely-advertised “$120 off” has been running continuously since at least December 2025 — treat it as the standard price, not a deadline.
2. Direct Meds
If you judge a company by what its actual customers say at scale, Direct Meds leads this page — narrowly. 4.6 out of 5 from about 14,500 Trustpilot reviews is the highest score and the highest volume on this page — though RemedyMeds has since closed the volume gap to a near tie, so read this as a two-horse race on customer evidence rather than a runaway. It is also the fastest: provider review within hours and 1–2 day fulfilment, with shipping included.
- The strongest third-party review base on this page, on both score and volume.
- Genuinely fast. Provider review within hours rather than days, 1–2 day fulfilment and free shipping — the shortest published path from signing up to injecting.
- A sublingual option as well as injectable, which matters more than it sounds if needles are the thing stopping you.
- Fast-growing and Utah-based, with company-reported growth from $8M to $80M in revenue between 2024 and 2025 and 125,000+ patients served.
- Worth knowing: the FDA sent Direct Meds a warning letter on 9 September 2025 over its marketing language, and its BBB file shows 272 complaints in three years and the bureau has moved its grade from B+ to “Not Rated.” Promotional pricing also varies by landing page — confirm the ongoing price, not just the first month.
3. TrimRx
TrimRx is the most straightforward proposition here, and for a lot of people that is exactly the appeal: one flat all-inclusive monthly price, no membership fee stacked on top, no insurance paperwork, and everything you need to inject arriving in a single cold-chain shipment. It is also BBB-accredited — the only program on this page that is.
- All-inclusive flat pricing — medication, consultation and supplies in one number, with no membership fee bolted on.
- BBB accreditation since 18 June 2025, a voluntary standards commitment none of the other three programs here has made.
- Everything arrives in the box — medication, syringes, needles, alcohol pads and a sharps container, cold-chain tracked, so there is no separate pharmacy trip on day one.
- All-inclusive flat pricing, verified — trimrx.com currently advertises plans from $179/month, with compounded semaglutide at $199/month all-inclusive per its own pricing guide (re-checked 2 September 2026).
- Worth knowing: TrimRx has published no outcome data of any kind, its BBB profile has no letter grade yet, and there is an active customer petition alleging delivery and refund problems. Orders also become non-refundable once intake is submitted.
4. MEDVi
MEDVi has the most format flexibility on this page: it is one of the few programs here offering a daily oral tablet as well as a weekly injection, and it runs a separate low-cost membership tier that routes to branded Wegovy or Zepbound. It is also large and profitable — the New York Times verified $401M in revenue and 250,000 customers for 2025. It still places sixth here, and the reasons are worth reading before you sign up.
- Oral tablets and injections, semaglutide or tirzepatide — the widest set of delivery formats of any program on this page.
- A branded route exists via a separate low-cost membership tier, for people who want Wegovy or Zepbound rather than a compounded product.
- Serious scale, independently verified: $401M revenue, $65M profit and roughly a quarter of a million customers in 2025.
- Worth knowing, and it is not a small thing: a May 2025 investigation documented AI-generated before-and-after photos, fabricated patient testimonials and fabricated doctor endorsements in MEDVi's marketing, and the New York Times later appended an editor's note to its own profile of the company.
- Also worth knowing: MEDVi received an FDA warning letter dated 20 February 2026, holds a BBB F grade with 719 complaints, and is not itself a pharmacy or a medical practice — clinical care and dispensing are contracted out to third parties.
All four, side by side
| Program | Compounded from | Ongoing | Standout strength | Read the terms for |
|---|---|---|---|---|
| 1. RemedyMeds | $179 first mo | $299/mo | Unlimited clinician access; same-dose switching | Cancellation; the evergreen “$120 off” |
| 2. Direct Meds | $147 promo | $249–$399/mo by product | Trustpilot 4.6 from ~14,500 reviews | Ongoing price; billing cadence |
| 3. TrimRx | From $179 | $199/mo | All-inclusive kit; BBB accredited | Non-refundable after intake |
| 4. MEDVi | $99 first mo (our offer link) | $299/mo | Oral tablet option; branded tier | BBB record; marketing claims |
How to choose in about five minutes
Step one: call your insurer, not the telehealth company. Ask whether your plan covers GLP-1 medication for weight management and what the copay is. None of the four cash-pay programs on this page bills insurance — so if the answer is yes, a prescription through your own doctor will usually beat any of them on both cost and regulatory footing. Come back here if the answer is no.
Step two: if you are paying cash, decide what you are optimising for. Lowest ongoing price we could verify is TrimRx at $199/month all-inclusive. Weight of customer evidence is Direct Meds. Most service in the price — unlimited clinician access, cold-chain shipping, seven-day support — is RemedyMeds. A daily tablet instead of an injection is MEDVi. These are genuinely different products and there is no wrong answer among them.
Step three: decide how you feel about compounded medication. Compounded semaglutide and tirzepatide are not FDA-approved and the FDA has not reviewed them for safety, effectiveness or quality. The shortages that made routine compounding lawful were declared resolved in December 2024 and February 2025, and the grace period ended in May 2025. Narrow 503A exceptions remain — a documented allergy to an inactive ingredient, or a genuinely non-standard dose — but cost saving alone is not one of them. On 30 April 2026 the FDA proposed removing all three molecules from the 503B Bulks List. Whichever program you pick, do not assume a twelve-month prepaid compounded plan will look the same in twelve months.
The FDA letters, in plain English
Three of the four programs on this page — Direct Meds, RemedyMeds and MEDVi — have received an FDA warning letter. We have said so in each card and we are saying so again here, because a roundup that quietly leaves this out is not worth reading.
What the letters are actually about matters, though. All three were part of a wave of more than fifty letters the FDA sent to telehealth marketers in this category, and in each case the agency objected to how the product was advertised — specifically, marketing that presented a compounded product as though it were equivalent to an FDA-approved branded drug. They are letters about advertising copy. They are not findings that anyone was harmed, and they are not recalls.
The practical takeaway for you is narrower than it sounds: a compounded GLP-1 is not the branded drug, whatever a landing page implies, and you should price and judge it as its own thing. If you want the FDA-approved branded product, the route is your own doctor and your insurer, not a cash-pay compounded program.
How we ranked, and what we could not verify
Independent editorial coverage of this category is close to non-existent. What fills search results instead is affiliate content, paid press releases reprinted as news, and “reviews” written by competitors. That is why this page cites Trustpilot, ConsumerAffairs, the BBB, the companies’ own live pages and named FDA documents, and almost nothing else. A third-party rating outranks a company claim; a company claim on its own gets reported as a company claim.
Things we could not establish, listed so you know where the edges are: TrimRx’s current Trustpilot review count, where sources disagree sharply; MEDVi’s live pricing, because its own pricing page returned unrendered template placeholders when we checked, so the figures above are third-party; and the recipient list for the 30 FDA warning letters announced on 3 March 2026, which was never published — so no claim can honestly be made about which companies were or were not on it.
Frequently asked questions
Which GLP-1 telehealth program is best?
RemedyMeds, for most people paying cash — it is the most complete package of the four, with unlimited clinician access, cold-chain shipping and the best switching experience. Direct Meds has the strongest verified customer review base, TrimRx the simplest all-inclusive flat price, and MEDVi the widest choice of formats including a daily oral tablet.
Which one is cheapest?
TrimRx has the lowest ongoing price we could verify — $199/month all-inclusive for compounded semaglutide, from $179 to start. MEDVi has the lowest starting price: $99 for the first month through our offer link, rising to $299/month after. Always price month two, not month one.
Which one has the best customer reviews?
Direct Meds, at 4.6 out of 5 from roughly 14,500 Trustpilot reviews — the highest score and the largest review base of the four, with RemedyMeds close behind at 4.6 from about 13,500.
Do any of them take insurance?
No — all four are cash-pay and none bills insurance for the medication, though all of them accept HSA and FSA cards. If your plan covers GLP-1 medication, a prescription through your own doctor may cost you less than any cash-pay program here — check that before paying cash.
Which ones include lab work?
RemedyMeds is the only one of the four that includes baseline bloodwork in the price, through Quest, BioReference or LabCorp per its help pages. Its medication page's inclusion list is less explicit than it used to be, so confirm at checkout. With the other three you arrange and pay for labs yourself.
Can I get an oral GLP-1 instead of an injection?
Yes, from three of the four. MEDVi offers daily oral tablets, Direct Meds offers sublingual drops, and TrimRx markets an oral option. RemedyMeds is injection-only.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is not FDA-approved. The FDA has not reviewed compounded products for safety, effectiveness or quality, and they are not the branded products. The FDA has sent multiple waves of warning letters to telehealth marketers in this category since September 2025, and several of those letters concern exactly this equivalence claim.
How is this page paid for?
The Weight Verdict earns a referral fee when a reader signs up through one of the links on this page. That is disclosed at the top and bottom of every page. The ranking above is based on third-party ratings, verified pricing and published terms — not on what each program pays.
Sources
- Trustpilot listings for directmeds.com, remedymeds.com and trimrx.com (ratings, review counts, response rates).
- ConsumerAffairs listing for MEDVi (2,185 reviews) and ConsumerAffairs listing for RemedyMeds.
- Better Business Bureau profiles for Direct Meds LLC, Remedy Meds LLC, MEDVi LLC and TrimRx.
- Forbes Health provider assessment of RemedyMeds (platform score 4.3 / 5).
- Live pricing checks on directmeds.com, remedymeds.com, glp1.medvi.org and trimrx.com, most recently 2 September 2026.
- Fierce Healthcare, Axios and MobiHealthNews reporting on the RemedyMeds acquisition of Thirty Madison, September 2025.
- The New York Times profile of MEDVi and its subsequent editor’s note; Futurism investigation into MEDVi marketing imagery, May 2025.
- FDA warning letters to Direct Meds and Remedy Meds (9 September 2025, MARCS-CMS 716830) and to MEDVi (20 February 2026, #721455).
- FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, 30 April 2026.
- FDA shortage resolution notices for semaglutide (December 2024) and tirzepatide (February 2025).
Figures on this page were checked on 4 August 2026; third-party ratings and complaint counts were re-checked on 27 August 2026, and prices were re-verified on the providers’ own pages on 2 September 2026. Prices, promotions and third-party ratings change frequently — always confirm the current price on the provider’s own checkout before you pay.